Home / KEEP BUT DO NOT DISPLAY / Facts / Novo Nordisk Gives Up on Victoza in T1D

Novo Nordisk Gives Up on Victoza in T1D

Aug 27, 2015

Lackluster results for liraglutide as adjunct to insulin therapy: Novo Nordisk announced that it will not pursue an expanded indication for liraglutide (Victoza) as an add-on treatment to insulin for type 1 diabetes because of disappointing phase III trial results. The company released top-line results for the ADJUNCT ONE randomized trial, in which nearly 1,400 people with type 1 diabetes were treated for 52 weeks with either placebo and insulin or with insulin and liraglutide. agonist. The liraglutide-insulin combination had little effect on HbA1c levels (mean baseline of about 8.2%). Specifically, those treated with 1.2 mg and 1.8 mg of liraglutide saw an improvement of around 0.5% versus 0.3% for those on placebo. However, the company stated that liraglutide as adjunct to insulin therapy “achieved the primary objective of non-inferiority in HbA1c.” — Novo Nordisk news release Aug. 25, 2015